Immune Prophylaxis Targeting the Respiratory Syncytial Virus (RSV) G Protein

The respiratory syncytial virus (RSV) causes significant respiratory disease in young infants and the elderly. Immune prophylaxis in infants is currently limited to palivizumab, an anti-RSV fusion (F) protein monoclonal antibody (mAb). While anti-F protein mAbs neutralize RSV, they are unable to pre...

Descripción completa

Detalles Bibliográficos
Autores principales: Bergeron, Harrison C., Murray, Jackelyn, Arora, Aakash, Nuñez Castrejon, Ana M., DuBois, Rebecca M., Anderson, Larry J., Kauvar, Lawrence M., Tripp, Ralph A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10221658/
https://www.ncbi.nlm.nih.gov/pubmed/37243153
http://dx.doi.org/10.3390/v15051067

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10221658/
https://www.ncbi.nlm.nih.gov/pubmed/37243153
http://dx.doi.org/10.3390/v15051067

Ejemplares similares